Moderna is one of the key pioneers of mRNA technology. The company has not only accelerated the development of innovative vaccines, but has also had a lasting impact on GMP inspections, quality assurance and regulatory requirements within the pharmaceutical industry.

Moderna and the breakthrough in mRNA technology

The biotechnology company Moderna has fundamentally transformed modern pharmacy in just a few years. Particularly during the COVID-19 pandemic, the use of mRNA took centre stage in international drug development. The technology enables genetic information to be specifically introduced into human cells so that they produce certain proteins. This allowed novel vaccines to be developed significantly faster than traditional Biosimilars.

With the global success of its vaccines, Moderna set new standards for the manufacture of drugs and compliance with regulatory requirements. At the same time, the demands placed on GMP inspections increased, as regulatory authorities had to assess the complex production processes in detail. In particular, the monitoring of active substance manufacturing, cleanrooms and documentation came under greater scrutiny from the authorities and every GMP inspectorate.

Issues such as quality assurance and critical process parameters (CPP) also became significantly more important for mRNA products. Due to the sensitive structure of the active substances, companies had to continuously optimise their production environments and testing procedures.

Challenges in GMP inspections of mRNA medicines

The manufacture of modern mRNA vaccines differs significantly from traditional pharmaceutical production processes. Regulatory authorities therefore examine with particular care, as part of a routine GMP inspection, whether all production steps have been validated and documented. These include, amongst other things, sterile manufacturing conditions, temperature monitoring and the control of microbiological risks.

Critical quality attributes (CQA) play a central role, particularly in innovative manufacturing processes. Even minor deviations can affect the stability and efficacy of a medicinal product. Regulatory authorities therefore require comprehensive evidence of process reliability and product quality.

Furthermore, companies must establish an effective deviation management system to identify and document potential quality defects at an early stage. If weaknesses are identified during an inspection, a follow-up GMP inspection may subsequently be required.

The lessons learnt from the pandemic have also led international regulatory authorities to tighten their requirements for GMP inspection reports. Particularly with regard to innovative production platforms, inspectors now pay greater attention to transparency, data integrity and traceability.

Modern production processes and their significance for the pharmaceutical industry

The development of mRNA technology has demonstrated just how significantly pharmaceutical technology has changed in recent years. Whilst traditional vaccines are often based on lengthy biological processes, mRNA enables a much more flexible production of new formulations.

Production involves, amongst other things, the use of highly specialised bioreactors, the operation of which must be strictly monitored. At the same time, the requirements regarding staff qualifications, documentation and technical infrastructure are increasing. The storage of these sensitive products also poses considerable challenges for companies and pharmaceutical warehouses.

The growing importance of innovative medicines is also changing the work of regulatory authorities, auditors and GMP experts in the long term. Many companies are therefore investing more heavily in modern quality systems and international GMP standards in order to pass future inspections successfully.

The implications of Moderna for the future of drug development

Moderna’s success has had a lasting impact on the entire pharmaceutical industry. Numerous manufacturers are now investing in mRNA-based medicines to treat infectious diseases, cancer or rare conditions. This is leading to the establishment of new production sites worldwide and placing additional demands on GMP inspections and international regulatory approval processes.

At the same time, the importance of specialised technical communication between manufacturers, regulatory authorities and international partners is growing. Precise technical expertise is indispensable, particularly during audits, regulatory inspections and the preparation of technical documentation.

Our experts support companies with professional pharmaceutical interpreters and specialist pharmaceutical translations for GMP inspections, audits and regulatory documents within the international pharmaceutical industry.

Image: Guido Hofmann, unsplash.com